- Home
- HCM vs BEAM Comparison
HCM vs BEAM Comparison
Compare HCM & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCM
- BEAM
- Stock Information
- Founded
- HCM 2000
- BEAM 2017
- Country
- HCM Hong Kong
- BEAM United States
- Employees
- HCM N/A
- BEAM N/A
- Industry
- HCM Biotechnology: Pharmaceutical Preparations
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HCM Health Care
- BEAM Health Care
- Exchange
- HCM Nasdaq
- BEAM Nasdaq
- Market Cap
- HCM 2.6B
- BEAM 2.6B
- IPO Year
- HCM N/A
- BEAM 2020
- Fundamental
- Price
- HCM $15.10
- BEAM $27.87
- Analyst Decision
- HCM Sell
- BEAM Strong Buy
- Analyst Count
- HCM 1
- BEAM 11
- Target Price
- HCM $13.75
- BEAM $49.40
- AVG Volume (30 Days)
- HCM 43.6K
- BEAM 2.5M
- Earning Date
- HCM 08-07-2025
- BEAM 11-05-2025
- Dividend Yield
- HCM N/A
- BEAM N/A
- EPS Growth
- HCM N/A
- BEAM N/A
- EPS
- HCM 0.53
- BEAM N/A
- Revenue
- HCM $602,197,000.00
- BEAM $60,272,000.00
- Revenue This Year
- HCM N/A
- BEAM N/A
- Revenue Next Year
- HCM $15.49
- BEAM $18.95
- P/E Ratio
- HCM $5.61
- BEAM N/A
- Revenue Growth
- HCM N/A
- BEAM N/A
- 52 Week Low
- HCM $11.51
- BEAM $13.53
- 52 Week High
- HCM $21.50
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- HCM 39.12
- BEAM 59.69
- Support Level
- HCM $14.86
- BEAM $26.90
- Resistance Level
- HCM $15.34
- BEAM $31.54
- Average True Range (ATR)
- HCM 0.32
- BEAM 2.10
- MACD
- HCM -0.06
- BEAM 0.05
- Stochastic Oscillator
- HCM 7.79
- BEAM 60.11
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.